My Patient Solutions

My Patient Solutions is a tool designed to help you enter and manage your patient cases with Genentech Access Solutions. Our easy-to-use online database tool offers you:

Rapid access to all patient case files for single and multi-office practices
Online completion, submission, printing and saving of the Statement of Medical Necessity (SMN) form
Easy enrollment for new cases, with your practice information automatically populated
Email and online alerts for your open cases
Notifications about the latest news and developments from Genentech Access Solutions
Quick links to the forms you need most often

Note: Register to use My Patient Solutions to obtain your unique User Name and Password before accessing the tool.

How My Patient Solutions Works

Once you have logged in, you can take the following actions in My Patient Solutions:

Find, sort and select a patient's open case record to view status and benefits investigation results.
Find, sort and select any closed patient case in the database.
Download and print any required forms for patient enrollment.
Enroll new patients for your practice online:
- Your practice information is automatically populated in the SMN by My Patient Solutions
- If the patient is already in our database, the demographic information is automatically populated by My Patient Solutions
- To enroll a new patient, you need the patient's contact and demographic information, insurance information, clinician information, medical history, prescribed therapy, indication and ICD-9 code(s)
Update information and quickly re-enroll existing patients.
View online alerts related to your patients' cases.
Sign up for email alerts related to your patients' cases.
See the latest news and updates from Genentech Access Solutions.

To start using My Patient Solutions now, please click on the log-in button in the upper right-hand corner of this screen. After you reach the My Patient Solutions log-in screen, you can click "Register Now" to request an account.

Avastin (bevacizumab) Indications and Important Safety Information

Indications

Avastin is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of:

Metastatic colorectal cancer, with intravenous 5-fluorouracil-based chemotherapy for first- or second-line treatment.
Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease.
Metastatic breast cancer, with paclitaxel for treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer.
- Effectiveness based on improvement in progression-free survival. No data available demonstrating improvement in disease-related symptoms or survival with Avastin.
- Not indicated for disease progression following anthracycline and taxane chemotherapy administered for metastatic disease.
Glioblastoma, as a single agent for patients with progressive disease following prior therapy.
- Effectiveness based on improvement in objective response rate. No data available demonstrating improvement in disease-related symptoms or survival with Avastin.
Metastatic renal cell carcinoma with interferon alfa

BOXED Warnings and Additional Important Safety Information

People receiving Avastin may experience side effects. In clinical trials, some people treated with Avastin experienced serious and sometimes fatal side effects, including:

Gastrointestinal (GI) perforation: Treatment with Avastin can result in the development of a potentially serious side effect called GI perforation, which is the development of a hole in the stomach, small intestine, or large intestine. In clinical trials, this event occurred in more people who received Avastin than in the comparison group (0.3% to 2.4%). In some cases, GI perforation resulted in fatality. Avastin therapy should be permanently stopped if GI perforation occurs.

Surgery and wound healing problems: Treatment with Avastin can lead to slow or incomplete wound healing (for example, when a surgical incision has trouble healing or staying closed). In some cases, this event resulted in fatality. Surgery and wound healing problems occurred more often in people who received Avastin than in the comparison group. Avastin therapy should not be started for at least 28 days after surgery and until the surgical wound is fully healed. The length of time between stopping Avastin and having voluntary surgery without the risk of having surgery and wound healing problems has not been determined. Treatment with Avastin should be stopped at least 28 days before voluntary surgery and in people with surgery and wound healing problems that require medical treatment.

Severe bleeding: Treatment with Avastin can result in serious bleeding, including coughing up blood, bleeding in the stomach, vomiting of blood, bleeding in the brain, nosebleeds, and vaginal bleeding. These events occurred up to 5 times more often in people who received Avastin. Across cancer types, 1.2% to 4.6% of people who received Avastin experienced severe to fatal bleeding. People who have recently coughed up blood (greater than or equal to a half teaspoon of red blood) or have serious bleeding should not receive Avastin. Treatment with Avastin should be permanently stopped if serious bleeding occurs (ie, requiring medical attention).

In clinical trials for different cancer types, there were additional serious and sometimes fatal side effects that occurred in more people who received Avastin than in those in the comparison group. The formation of an abnormal passage from parts of the body to another part (non-GI fistula formation) was seen in 0.3% or less of people. Severe to life-threatening stroke or heart problems were seen in 2.4% of people. Too much protein in the urine, which led to kidney problems, was seen in less than 1% of people. Additional serious side effects that occurred in more people who received Avastin than those in the comparison group included severe to life-threatening high blood pressure, which was seen in 5% to 18% of people, and nervous system and vision disturbances (reversible posterior leukoencephalopathy syndrome), which was seen in less than 0.1% of people. Infusion reactions with the first dose of Avastin were uncommon and occurred in less than 3% of people, and severe reactions occurred in 0.2% of people.

Common side effects that occurred in more than 10% of people who received Avastin for different cancer types, and at least twice the rate of the comparison group, were nosebleeds, headache, high blood pressure, inflammation of the nose, too much protein in the urine, taste change, dry skin, rectal bleeding, tear production disorder, back pain, and inflammation of the skin (exfoliative dermatitis). Across all trials, treatment with Avastin was permanently stopped in 8.4% to 21% of people because of side effects.

Avastin may impair fertility. If you are pregnant or thinking of becoming pregnant, talk with your doctor about the potential risk of loss of the pregnancy or the potential risk of Avastin to the fetus during and following Avastin therapy, and the need to continue an effective birth control method for at least 6 months following the last dose of Avastin.

Please see full Product Information, including Boxed WARNINGS, for additional safety information.

Avastin^® is a registered trademark and the Access Solutions logo and the Access Solutions Treatment made possible logo are trademarks of Genentech USA, Inc.